7N0A
 
 | | Structure of Human Leukaemia Inhibitory Factor with Fab MSC1 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, Leukemia inhibitory factor, ... | | Authors: | Raman, S, Bosch, A, Fransson, J, Julien, J.P. | | Deposit date: | 2021-05-25 | | Release date: | 2022-06-15 | | Last modified: | 2023-10-25 | | Method: | X-RAY DIFFRACTION (3.1 Å) | | Cite: | Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment.
Clin.Cancer Res., 29, 2023
|
|
6O3A
 | | Crystal structure of Frizzled 7 CRD in complex with F7.B Fab | | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID, ... | | Authors: | Raman, S, Beilschmidt, M, Fransson, J, Julien, J.P. | | Deposit date: | 2019-02-26 | | Release date: | 2019-04-03 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies.
Proc. Natl. Acad. Sci. U.S.A., 116, 2019
|
|
6O39
 | | Crystal structure of Frizzled 5 CRD in complex with F2.I Fab | | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, ACETATE ION, ... | | Authors: | Raman, S, Beilschmidt, M, Fransson, J, Julien, J.P. | | Deposit date: | 2019-02-26 | | Release date: | 2019-04-03 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies.
Proc. Natl. Acad. Sci. U.S.A., 116, 2019
|
|
6O3B
 | | Crystal structure of Frizzled 7 CRD in complex with F6 Fab | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Antibody Fab F6, Heavy chain, ... | | Authors: | Raman, S, Beilschmidt, M, Fransson, J, Julien, J.P. | | Deposit date: | 2019-02-26 | | Release date: | 2019-04-03 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies.
Proc. Natl. Acad. Sci. U.S.A., 116, 2019
|
|
